Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)

AIMS: Ixekizumab is a high‐affinity monoclonal antibody that selectively targets interleukin‐17A used in the treatment of adult and paediatric patients with moderate‐to‐severe psoriasis. This analysis evaluated the pharmacokinetics (PK) of ixekizumab and the exposure–efficacy relationship in paediat...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Kimberley, Chua, Laiyi, Velez de Mendizabal, Nieves, Pitou, Celine, Rodriguez Capriles, Claudia, Paller, Amy S., Lansang, Perla, Seyger, Marieke M. B., Papp, Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291793/
https://www.ncbi.nlm.nih.gov/pubmed/34378230
http://dx.doi.org/10.1111/bcp.15034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291793/
https://www.ncbi.nlm.nih.gov/pubmed/34378230
http://dx.doi.org/10.1111/bcp.15034

Ejemplares similares